Testing a blood marker to predict pancreatic cancer outcomes
Treatments studied
Part of Cancer clinical trials.
This study looks at a test called RPSA to see if it can help predict how pancreatic cancer may turn out. It includes people being treated at Reims University Hospital for pancreatic tumors that can be removed (or may become removable).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are being treated at Reims University Hospital for a pancreatic tumor that is resectable or possibly resectable
- You may have chemotherapy before surgery (neoadjuvant) or not
- A doctor has confirmed pancreatic cancer (PDAC) as the diagnosis
- You must sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
This study looks for markers in tumor tissue that could help find pancreatic cancer earlier. You may be able to join if you are having surgery for a suspected pancreatic tumor and the final diagnosis is a precancerous condition or pancreatic cancer.
This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This study looks at people with non-metastatic, difficult-to-operate pancreatic cancer to better understand how treatment is selected and adjusted at different stages. It may help by testing a “dynamic” approach to assessment over time, before and alongside planned treatment.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.